<DOC>
	<DOC>NCT00102947</DOC>
	<brief_summary>This is a Phase 4, randomized, open-label, multicenter, comparative study designed to further evaluate the pharmacokinetics of intravenous (i.v.) daptomycin and the safety and efficacy of daptomycin relative to comparator in the treatment of complicated skin and skin structure infections in patients with renal impairment.</brief_summary>
	<brief_title>Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>Moderate to endstage renal impairment A diagnosis of complicated skin and skin structure infection known or suspected to be due to susceptible Grampositive bacteria based on positive Gram stain A diagnosis of bacterial skin and skin structure infection in the presence of some complicating factor Known bacteremia, osteomyelitis or endocarditis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>renal impairment</keyword>
	<keyword>daptomycin</keyword>
	<keyword>Cubist</keyword>
	<keyword>complicated skin and skin structure infections</keyword>
</DOC>